Phenobarbital Treatment for Prolonged Cholestatic Jaundice After Endoscopic Retrograde Cholangiopancreatography

Prolonged cholestatic jaundice after endoscopic retrograde cholangiopancreatography (ERCP) is a rare and clinically challenging condition when mechanical obstruction is excluded. While its pathophysiology remains unclear and no established treatment strategy exists, we describe a patient with persistent post-ERCP cholestasis whose hyperbilirubinemia improved markedly after initiation of phenobarbital. The total bilirubin level decreased from a peak of 29.8 mg/dL to 23.9 mg/dL within 5 days and continued to decline thereafter. This suggests that phenobarbital could be a potential therapeutic option for prolonged post-ERCP cholestasis when conventional treatments, such as ursodeoxycholic acid and herbal medicine, are ineffective.

Authors

Institutions

Publication Details

Journal
ACG Case Reports Journal
Published
2026-05-01
DOI
https://doi.org/10.14309/crj.0000000000002123
Primary Topic
Gallbladder and Bile Duct Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phenobarbital Treatment for Prolonged Cholestatic Jaundice After Endoscopic Retrograde Cholangiopancreatography

Yutaka Honda, Masaaki Takamura, Hiromitsu Oka, Oki Nakano et al.
ACG Case Reports Journal
Gallbladder and Bile Duct Disorders
article

Phenobarbital Treatment for Prolonged Cholestatic Jaundice After Endoscopic Retrograde Cholangiopancreatography

Yutaka Honda, Masaaki Takamura, Hiromitsu Oka, Oki Nakano, Toru Matsui, Takumi Yoneyama
article en

Abstract

Prolonged cholestatic jaundice after endoscopic retrograde cholangiopancreatography (ERCP) is a rare and clinically challenging condition when mechanical obstruction is excluded. While its pathophysiology remains unclear and no established treatment strategy exists, we describe a patient with persistent post-ERCP cholestasis whose hyperbilirubinemia improved markedly after initiation of phenobarbital. The total bilirubin level decreased from a peak of 29.8 mg/dL to 23.9 mg/dL within 5 days and continued to decline thereafter. This suggests that phenobarbital could be a potential therapeutic option for prolonged post-ERCP cholestasis when conventional treatments, such as ursodeoxycholic acid and herbal medicine, are ineffective.

ACG Case Reports JournalVol. 13(5)
Niigata City General Hospital (JP)
Good health and well-being
Openalex Percentile: Top 8%
Gallbladder and Bile Duct Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.